Drug intelligence / Profile preview

ZW1572

Development stage: Preclinical
Lead developer: Zymeworks
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous (potential/anticipated)

Overview

ZW1572 is a preclinical-stage bispecific antibody developed by Zymeworks. It targets both interleukin-31 (IL-31) and interleukin-4 receptor alpha (IL-4Rα), functioning as an inhibitor of these pathways. The drug is designed for the treatment of atopic dermatitis, with potential applications in other immune system and skin diseases. By simultaneously blocking IL-31 and IL-4Rα signaling, ZW1572 aims to modulate key drivers of inflammation implicated in atopic dermatitis and related conditions[1][5]. Its bispecific design may offer advantages over monospecific therapies by addressing multiple inflammatory pathways.

Targets

IL4R (Interleukin-4 receptor alpha subunit)IL31 (IL-31)

Beyond the preview

Go deeper on ZW1572.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZW1572.

Explore the full profile